 "Suven Life Sciences surges on bagging three product patents")
Suven Life Sciences climbs 5% on receiving one product patent each from New Zealand, Singapore and USA corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2032.
After receiving these new patents, the company has now a total of 24 granted patents from New Zealand, 22 granted product patents from Singapore and 22 granted patents from USA. These granted patents are exclusive intellectual property of Suven and are attained via the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Venkat Jasti, CEO of Suven stated that Suven is very pleased by the grant of these patents for the pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.
The stock opened at Rs 270 and touched a high of Rs 283 on the BSE . A total of 496,700 shares changed hands on the BSE so far.
